Next Pharmaceuticals, Irvine, CA, has appointed Stauber Performance Ingredients, Fullerton, CA, exclusive U.S. marketing representative for its new COX-2 inhibitor, Nexrutine™. The patent-pending Nexrutine will now be available to manufacturers throughout the U.S. through Stauber’s marketing channels and multiple facilities.